Document is current
Any future updates will be listed below
-
Authors
Cartron, Guillaume https://orcid.org/0000-0003-0659-9635
Houot, Roch https://orcid.org/0000-0003-1729-8213
Al Tabaa, Yassine
Le Bras, Fabien
Ysebaert, Loïc
Choquet, Sylvain https://orcid.org/0000-0002-7791-0470
Jardin, Fabrice https://orcid.org/0000-0002-6804-7943
Bay, Jacques-Olivier https://orcid.org/0000-0002-7032-5180
Gros, François-Xavier https://orcid.org/0000-0001-8998-3039
Morschhauser, Franck
Casasnovas, Olivier
Gastinne, Thomas
Thieblemont, Catherine https://orcid.org/0000-0002-9941-2448
Joris, Magalie
Ricard, Laure
Regny, Caroline
Drieu La Rochelle, Laurianne
Feugier, Pierre
Marcais, Ambroise https://orcid.org/0000-0002-6844-7920
Griolet, Samuel
Tarte, Karin https://orcid.org/0000-0002-6809-917X
Laurent, Camille
Sesques, Pierre
- License Information
-
More Information
Article History
Received: 22 November 2024
Accepted: 5 March 2025
First Online: 3 April 2025
Competing interests
: G.C. has received honoraria and advisory/consultancy fees from Roche, Bristol-Myers Squibb, BeiGene, Novartis, Kite/Gilead, Takeda, AstraZeneca, AbbVie, Janssen, Onward Therapeutics and Mabqi. R.H. has received honoraria from Kite/Gilead, Novartis, Incyte, Janssen, MSD, Takeda and Roche and is a member on the board of directors or advisory committee of Kite/Gilead, Novartis, Bristol-Myers Squibb/Celgene, ADC Therapeutics, Incyte and Miltenyi. L.Y. has received honoraria and advisory/consultancy fees from AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb/Celgene, Gilead/Kite, Janssen and Roche. S.C. has received honoraria and advisory/consultancy fees from AbbVie, AstraZeneca, Atara, BeiGene, Gilead/Kite, Janssen, Novartis, Pierre Fabre and Takeda. F.J. has received honoraria and advisory/consultancy fees from Roche, Bristol-Myers Squibb, Novartis, Kite/Gilead, Takeda, AbbVie and Janssen. F-X.G. has received honoraria and advisory/consultancy fees from Bristol-Myers Squibb, Novartis, Kite/Gilead, AstraZeneca, Janssen and Miltenyi. F.M. has received consultancy fees from AbbVie, Bristol-Myers Squibb, Gilead, Novartis and Roche, serves as an advisor for AbbVie, Gilead and Roche and has received honoraria from Chugai and Kaleda for scientific lectures. O.C. has received honoraria and advisory/consultancy fees from Roche, Takeda, Gilead/Kite, Bristol-Myers Squib, MSD, AbbVie, BeiGene and ADC therapeutics. T.G. has received travel and accommodation expenses from Roche. C.T. has received honoraria and advisory/consultancy fees from Roche, Bristol-Myers Squibb, Novartis, Kite/Gilead, Takeda, AbbVie and Janssen. L.D.L.R. has received honoraria and advisory/consultancy fees from Gilead/Kite, Novartis, Bristol-Myers Squibb, Janssen and Takeda. P.F. has received honoraria and advisory/consultancy fees from BeiGene, Kite/Gilead, AstraZeneca, AbbVie and Janssen. S.G. is an employee of LYSARC. P.S. has received honoraria and advisory/consultancy fees from Janssen, Roche, Bristol-Myers Squibb, AbbVie, AstraZeneca, Chugai, Novartis and Kite/Gilead. Y.A.T., M.J., C.L., F.L.B., A.M., J-O.B., C.R., L.R. and K.T. declare no competing interests.
